LTB4-driven inflammation and increased expression of ALOX5/ACE2 during severe COVID-19 in individuals with diabetes (Preprint)

dc.creatorBonyek-Silva, Icaro
dc.creatorMachado, Antônio Fernando Araujo
dc.creatorSilva, Thiago Cerqueira
dc.creatorNunes, Sara
dc.creatorCruz, Marcio Rivison Silva
dc.creatorSilva, Jessica
dc.creatorSantos, Reinan Lima
dc.creatorBarral, Aldina Maria do Prado
dc.creatorOliveira, Pablo Rafael Silveira
dc.creatorKhouri, Antonio Ricardo
dc.creatorSerezani, C. Henrique
dc.creatorBrodskyn, Claudia Ida
dc.creatorCaldas, Juliana Ribeiro
dc.creatorManoel, Barral Netto
dc.creatorBoaventura, Viviane
dc.creatorTavares, Natalia Machado
dc.date2022-01-07T21:27:42Z
dc.date2022-01-07T21:27:42Z
dc.date2021
dc.date.accessioned2023-09-26T21:11:45Z
dc.date.available2023-09-26T21:11:45Z
dc.identifierBONYEK-SILVA, Icaro et al. LTB4-Driven Inflammation and Increased Expression of ALOX5/ACE2 During Severe COVID-19 in Individuals With Diabetes. Diabetes, p. 1-47, 15 Jun. 2021.
dc.identifier0012-1797
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/50680
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8870649
dc.descriptionDiabetes is a known risk factor for severe COVID-19, the disease caused by the new coronavirus SARS-CoV-2. However, there is a lack of knowledge about the mechanisms involved in the evolution of COVID-19 in individuals with diabetes. Therefore, we aimed to evaluate whether the chronic low-grade inflammation of diabetes could play a role in the development of severe COVID-19. We collected clinical data and blood samples of hospitalized patients for COVID-19, with diabetes and without diabetes. Plasma samples were used to measure inflammatory mediators and peripheral blood mononuclear cells, for gene expression analysis of SARS-CoV-2 main receptor system (ACE2/TMPRSS2) and main molecule of LTB4 pathway (ALOX5). We found that diabetes activates LTB4 pathway, and during COVID-19, it increases ACE2/TMPRSS2 as well as ALOX5 expression. Diabetes was also associated with COVID-19-related disorders, such as reduced SpO2/FiO2 and PaO2/FiO2 levels, and increased disease duration. In addition, the expression of ACE2 and ALOX5 are positively correlated, with increased expression in COVID-19 patients with diabetes requiring intensive care assistance. We confirmed these molecular results at the protein level, where plasma LTB4 is significantly increased in individuals with diabetes. Besides, IL-6 serum levels are increased only in individuals with diabetes requiring intensive care assistance. Together, these results indicate that LTB4 and IL-6 systemic levels, as well as, ACE2/ALOX5 blood expression could be early markers of severe COVID-19 in individuals with diabetes.
dc.formatapplication/pdf
dc.languageeng
dc.publisherAmerican Diabetes Association
dc.relationhttps://www.arca.fiocruz.br/handle/icict/49900
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectDiabetes
dc.subjectSARS-CoV-2
dc.subjectLTB4
dc.subjectACE2
dc.subjectCOVID-19
dc.subjectDiabetes
dc.subjectLipid mediators
dc.subjectLTB4
dc.subjectACE2
dc.subjectSARS-CoV-2
dc.titleLTB4-driven inflammation and increased expression of ALOX5/ACE2 during severe COVID-19 in individuals with diabetes (Preprint)
dc.typePreprint


Este ítem pertenece a la siguiente institución